Related Experiment Video
Updated: Feb 26, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
Hepatitis B and C Viruses and Biologics
1Division of Dermatology, Department of Medicine, University of Calgary, Calgary, AB, Canada.
Abstract:
Hepatitis B virus (HBV) and hepatitis C virus (HCV) are common, worldwide viral illnesses that potentially impact the clinician's ability to manage patients with immunosuppressive medications such as biological therapy. In light of recent literature reviews, patients with HBV and HCV should be referred to a hepatologist or infectious disease expert prior to initiation of biological therapy.
Related Concept Videos
Retrovirus Life Cycles
Drug Products: Biologics, Biosimilars and Interchangeables
Viruses with RNA Genomes
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Microorganisms in Medicine and Therapeutics

